SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
409,099
408,897
302,238
215,003
144,427
Cost of Revenue
16,123
15,356
15,215
11,986
8,423
Gross Profit
392,976
393,541
287,023
203,017
136,004
Operating Expenses
Research Development
82,627
89,209
49,577
42,791
29,135
Selling General and Administrative
164,993
159,888
137,905
106,010
89,204
Total Operating Expenses
247,620
249,097
187,482
148,801
118,339
Operating Income or Loss
145,356
144,444
99,541
54,216
17,665
Interest Expense
22,340
18,111
1,568
5,091
1,229
Total Other Income/Expenses Net
-
-
-219
-238
-2,107
Income Before Tax
142,123
140,176
100,618
50,369
14,972
Income Tax Expense
37,152
29,183
43,334
-40,852
956
Income from Continuing Operations
104,971
110,993
57,284
91,221
14,016
Net Income
104,971
110,993
57,284
91,221
14,016
Net Income available to common shareholders
104,971
110,993
57,284
91,221
14,016
Reported EPS
Basic
-
2.13
1.13
1.84
0.30
Diluted
-
2.05
1.08
1.76
0.28
Weighted average shares outstanding
Basic
-
51,990
50,757
49,472
47,485
Diluted
-
54,099
53,301
51,709
51,160
EBITDA
-
158,287
102,186
55,460
16,201